OT mobile menu

Search form


Breast Cancer Targets

Treating Bone Loss in Breast Cancer

A new study has identified how bones get damaged from breast cancer and researchers are developing a new drug to mitigate this problem. Image © JKSippapas/Shutterstock.com


Breast Cancer Targets

A new study is suggesting that testing for variants in seven cancer-associated genes followed by risk-reduction management could cost-effectively improve life expectancy for women at risk for hereditary breast cancer.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

A new population-based study is suggesting that there are significant racial disparities in gene expression profiling testing in women with breast cancer.

The FDA has approved ribociclib in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.

Scientists from Dana-Farber Cancer Institute found that a compound that can reverse the function of innate immune system cells—to fight tumors rather than encourage growth—caused breast tumors in mice to shrink and withdraw from distant metastases.


Subscribe to Breast Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.